PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
32.68%
Some net income increase while AGEN is negative at -103.62%. John Neff would see a short-term edge over the struggling competitor.
80.19%
D&A growth well above AGEN's 124.52%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-398.37%
Negative yoy deferred tax while AGEN stands at 100.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
30.65%
Less SBC growth vs. AGEN's 114.54%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
27.89%
Less working capital growth vs. AGEN's 119.49%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.29%
Both negative yoy AP, with AGEN at -261.48%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
66.06%
Growth well above AGEN's 59.09%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
30.65%
Well above AGEN's 7.51%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-19.98%
Both yoy CFO lines are negative, with AGEN at -9.91%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-32.37%
Both yoy lines negative, with AGEN at -98.85%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-271.58%
Both yoy lines negative, with AGEN at -30.49%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
69.11%
Debt repayment growth of 69.11% while AGEN is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-69.14%
Negative yoy issuance while AGEN is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.